ALKS
Alkermes plc
$27.35
Earnings Summary
Revenue | $412.73Mn |
Net Profits | $-5.35Mn |
Net Profit Margins | -1.3% |
Highlights
Alkermes plc’s revenue jumped 30.71% since last year same period to $412.73Mn in the Q4 2019. On a quarterly growth basis, Alkermes plc has generated 61.7% jump in its revenue since last 3-months.
Alkermes plc’s net profit jumped 44.88% since last year same period to $-5.35Mn in the Q4 2019. On a quarterly growth basis, Alkermes plc has generated 89.87% jump in its net profits since last 3-months.
Alkermes plc’s net profit margin jumped 57.83% since last year same period to -1.3% in the Q4 2019. On a quarterly growth basis, Alkermes plc has generated 93.74% jump in its net profit margins since last 3-months.
Earnings per share (EPS) Estimates
Earnings per share (EPS) estimates of the Alkermes plc post its latest quarter earnings
EPS Estimate Current Quarter | -0.12 |
EPS Estimate Current Year | -0.12 |
Highlights
Alkermes plc’s earning per share (EPS) estimates for the current quarter stand at -0.12 - a -518.18% fall from last quarter’s estimates.
Alkermes plc’s earning per share (EPS) estimates for the current year stand at -0.12.
Key Ratios
Key ratios of the Alkermes plc post its Q1 2023 earnings
Earning Per Share (EPS) | 0 |
Highlights
Alkermes plc’s earning per share (EPS) fell -100% since last year same period to 0 in the Q1 2023. This indicates that the Alkermes plc has generated -100% annual rate of fall in its earning per share (EPS) in the last 4 quarters.
Earnings Calendar
| Earnings Date | Estimated EPS | Reported EPS | Surprise % |
|---|---|---|---|
2018-02-16 | 0.23 | 0.31 | 34.78% |
2017-07-27 | -0.01 | 0.01 | 200% |
2017-04-27 | -0.09 | -0.18 | -100% |
2017-10-26 | -0.01 | 0.03 | 400% |
Company Information
Alkermes plc is a fully integrated, global biopharmaceutical company developing innovative medicines in the fields of neuroscience and oncology. The company has a portfolio of proprietary commercial products focused on addiction and schizophrenia, and a pipeline of product candidates in development for schizophrenia, bipolar I disorder, neurodegenerative disorders, and cancer. Headquartered in Dublin, Ireland, Alkermes plc has an R&D center in Waltham, Massachusetts; a research and manufacturing facility in Athlone, Ireland; and a manufacturing facility in Wilmington, Ohio.
Organisation | Alkermes plc |
Headquarters | Connaught House, Dublin, Ireland, 4 |
Employees | 2211 |
Industry | Health Technology |
CEO | Richard F. Pops |
Discover More Earning Stocks in Health Technology Sector
Trading and brokerage services provided by
Banking and Remittance services provided by
Technology services provided by : Finzoomers Services Private Limited
Disclaimer: These services are not for exchange traded products.The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Finzoomers Services Private Limited acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*